Yes, you can sell a private label SCCM serum in both the US and the EU, but the two markets require separate regulatory compliance pathways, and launching simultaneously takes advance planning — typically 14–20 weeks from formula lock if you initiate both tracks in parallel.
United States (FDA / MoCRA): Under the Modernization of Cosmetics Regulation Act of 2022, effective December 2023, your product requires: (1) the manufacturing facility to be FDA-registered; (2) product listing with the FDA, including the product name, responsible company, cosmetic category, and ingredient list; (3) allergen and safety substantiation documentation maintained internally. For human-derived SCCM specifically, you must ensure the formula uses cosmetic-grade raw materials with no drug claims — avoid terms like 'regenerates tissue,' 'stimulates cell production,' or 'repairs DNA damage' in your US marketing copy, as these can trigger drug reclassification scrutiny.
European Union (EU Cosmetics Regulation EC 1223/2009): You must appoint an EU Responsible Person (RP) — a legal entity established in the EU/EEA — before any product can be placed on the EU market. The RP maintains your Product Information File (PIF), which includes the Cosmetic Product Safety Report (CPSR), formula details, manufacturing method, stability data, and PET results. For human-derived SCCM, there is meaningful regulatory risk: ingredients of human origin are subject to heightened EU safety review, and some may be restricted under Annexes II or III of the regulation. Many founders targeting the EU market use plant stem cell culture filtrates (e.g., Malus domestica fruit cell culture, Leontopodium alpinum meristem culture) specifically to sidestep this complexity, while maintaining strong 'stem cell technology' marketing positioning.
Practical dual-market strategy: Commission a formula with two SCCM options — a human-derived variant for the US SKU and a plant-derived variant for the EU SKU — and use the same base, packaging, and secondary actives for both. This approach lets you present a unified brand while maintaining compliant ingredient lists in each market. Alternatively, use a plant-derived SCCM for both markets to simplify your supply chain and regulatory burden at a modest trade-off in marketing narrative strength.
Cost add for EU compliance: Engaging an EU RP costs $500–$2,000/year per product line. A CPSR from a qualified EU safety assessor costs $1,200–$3,500 per formula, and EU product notification via the CPNP portal is free but must be completed before the product is sold. Budget an additional 6–8 weeks beyond your US timeline for EU CPSR completion if you start the safety assessment process at formula lock.
AJ Cosmo Labs connects founders with manufacturers and compliance consultants who handle multi-market launches — when posting your brief in the app, indicate your target markets so matched manufacturers can flag their EU regulatory support capability upfront.
Read the full guide on Private Label Stem Cell Conditioned Media Serum Manufacturer →